CF PHARMTECH's candidate drug ICF00 clinical trial application has been accepted
CF PHARMTECH (02652.HK) announced that its self-developed inhalation powder candidate drug ICF001 has been accepted for clinical trial application by the National Medical Products Administration of China. ICF001 is an innovative long-acting inhalation powder candidate drug developed based on a prodrug technology platform, specifically designed for the treatment of pulmonary arterial hypertension and related severe pulmonary diseases
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments